How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

932 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Human papilloma virus genotypes in women from Nayarit, Mexico, with squamous intraepithelial lesions and cervical cancer Full Text available with Trip Pro

Human papilloma virus genotypes in women from Nayarit, Mexico, with squamous intraepithelial lesions and cervical cancer In Mexico cervical cancer (CC) is the most common cause of death from neoplasia in women. Study aimed to analyze the current distribution of Human papillomavirus (HPV) types in women from Nayarit, Mexico, with Squamous intraepithelial lesions (SIL) and Cervical cancer (CC).Between January 2011 and July 2013, cervical samples were collected from female residents of the Mexican (...) was the most prevalent genotype identified and was frequently present as a co-infection with HPV types 18, 51, 52, 59, 66, or 70.Women <20 years of age were most often infected with HPV, and the HPV Quadrivalent vaccine (types 16, 18, 6, and 11), currently available in Mexico, no confers protection against a subset of the HPV genotypes identified in the present study (58, 31, 70, and 35). Thus, it is important evaluate the geographical distribution of specific HPV genotypes in all health of center across

2016 International journal of health sciences

182. A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers Full Text available with Trip Pro

A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide and is etiologically linked to several cancers, including cervical and genital cancers. NKG2D, an activating receptor expressed by NK cells, plays an important role in cancer immune-surveillance. We analyzed the impact of a NKG2D gene variant, rs1049174

2016 Scientific reports

183. Estimation of utility weights for human papilloma virus-related health states according to disease severity Full Text available with Trip Pro

Estimation of utility weights for human papilloma virus-related health states according to disease severity A cost-utility study of a human papilloma virus (HPV) vaccine requires that the utility weights for HPV-related health states (i.e., cervical intraepithelial neoplasia (CIN), cervical cancer, and condyloma) be evaluated. The aim of the present study was to determine the utility weights for HPV-related health states.Hypothetical standardised health states related to HPV were developed (...) based on patient education material and previous publications. To fully reflect disease progression from diagnosis to prognosis, each health state comprised four parts (diagnosis, symptoms, treatment, and progression and prognosis). Nine-hundred members from the Korean general population evaluated the HPV-related health states using a visual analogue scale (VAS) and a standard gamble (SG) approach, which were administered face-to-face via computer-assisted interview. The mean utility values were

2016 Health and quality of life outcomes

184. Human papilloma virus in oral cancer Full Text available with Trip Pro

Human papilloma virus in oral cancer Cervical cancer is the second most prevalent cancer among women, and it arises from cells that originate in the cervix uteri. Among several causes of cervical malignancies, infection with some types of human papilloma virus (HPV) is well known to be the greatest cervical cancer risk factor. Over 150 subtypes of HPV have been identified; more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region and oral (...) cavity. The recently introduced vaccine for HPV infection is effective against certain subtypes of HPV that are associated with cervical cancer, genital warts, and some less common cancers, including oropharyngeal cancer. Two HPV vaccines, quadrivalent and bivalent types that use virus-like particles (VLPs), are currently used in the medical commercial market. While the value of HPV vaccination for oral cancer prevention is still controversial, some evidence supports the possibility that HPV

2016 Journal of the Korean Association of Oral and Maxillofacial Surgeons

185. More Gardasil fear mongering: A “critical review” of HPV vaccination that lacks critical thinking

vaccines against the human papilloma virus (HPV), the virus that causes genital wart and certain subtypes of which greatly predispose to cancer. The reason for the extreme negative reaction to HPV vaccines is not because they are thought to cause autism, given that they are not administered until girls are approaching pubert. Rather, it is because they are falsely considered to be unnecessary. HPV is sexually transmitted disease, which makes the cervical cancer HPV vaccines prevent a largely sexually (...) and antivaccine quackery), inevitably you see the same misinformation and lies pop up… It never ceases to amaze me just how ignorant of very basic principles of science anti-vaccine activists often are. I mean, seriously. Every time they try to post something, whether they know it or not, they end up making themselves look so very, very stupid--or at least ignorant. The Dunning-… Vaccines against the human papilloma virus (HPV), such as Gardasil and Cervarix, seem to have a strange power over people who

2017 Respectful Insolence

186. Another antivaccine film disguised as a documentary, this time lying about HPV vaccines

happy to have to write this post, but a blogger's got to do what a blogger's got to do. The reason is that Katie Couric has done something requires—nay, demands—a heapin' helpin' of Orac's characteristic Respectful Insolence. Why should I give the proverbial rodent's posterior about… As mentioned in the comments to this post, there is a brewing controversy over upcoming guidelines outlining who should receive the "cervical cancer vaccine," a vaccine against the human papilloma virus (HPV). Briefly (...) , the HPV vaccine is a highly effective (100% in a 2-year clinical trial) vaccine… Focus on the Family, a conservative social organization located in Colorado Springs, CO, has decided to oppose the mandatory vaccination of young girls for Human Papilloma Virus (HPV), a virus linked to the formation of cervical cancer. Recently the FDA has approved a vaccine for two of the high… An infinite loop of crazy-- Apparently Michele Bachmann (Crazy, MN) wants her daughters (and any/all women) to get cervical

2017 Respectful Insolence

187. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Full Text available with Trip Pro

and intravenous fluids, but all made a full recovery. Denominators were not available for all vaccines so an overall incidence was not calculated, however the estimated incidence was 12.0 per 100,000 dose for single component measles vaccine and 1.4 cases per million doses for the bivalent human papilloma virus vaccine (Cervarix, GSK).Anaphylaxis remains a rare adverse event following immunisation. No cases were related to vaccines given as part of the 'routine' infant and preschool immunisation programme (...) Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Anaphylaxis is a rare adverse event following immunisation (AEFI) and unlikely to be detected in prelicensure vaccine trials. Previous retrospective studies have been hampered by the paucity of information available to passive reporting schemes. The aim of the present study was to estimate the incidence and clinical presentation of anaphylaxis as an AEFI using prospective active surveillance.Children under 16

2012 Archives of Disease in Childhood

188. Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer

whether a specially designed vaccine, based on a genetically modified strain of the bacterium Listeria monocytogenes and called ADXS11-001 is safe to use and is able to boost the immune system of patients presenting with Human Papilloma Virus (HPV) associated oropharyngeal cancer (OPSCC). It is hoped that the vaccine will boost the immune system so that immune cells with cell killing properties are able to attack any cancer cells remaining after the patients have been treated. However, the vaccine (...) : REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma Study Start Date : February 2012 Actual Primary Completion Date : November 2014 Actual Study Completion Date : November 2014 Arms and Interventions Go to Intervention Details: Biological: ADXS11-001 Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu

2012 Clinical Trials

189. Gynecologic Care for Women and Adolescents With Human Immunodeficiency Virus

cytology and human papilloma- virus [HPV] screening) is not recommended for HIV-infected women younger than 30 years. Women infected with HIV who are 30 years and older can be screened with cytology alone or co-testing. After women screened with cytology alone have had three consecutive annual test results that are normal, follow-up screening can be every 3 years. Women infected with HIV who have one negative co-test result (normal cytology and HPV negative) can have their next cervical cancer (...) vaccination for primary prevention should be administered to HIV-infected females following the same guidelines as for uninfected females (11, ). Although the Panel on Opportunistic Infections acknowledged that there are no specific data on efficacy of the vaccine in HIV-infected women, there are studies confirming safety and immunogenicity ( ). Condyloma should be managed according to the current published by the Centers for Disease Control and Prevention (CDC) (11, 24). Women with immunosuppression may

2016 American College of Obstetricians and Gynecologists

190. MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Collaborator: Novartis Information provided by (Responsible Party): Hee Jin Cheong, Korea University Guro Hospital Study Details Study Description Go to Brief Summary: Similar to children, adults frequently visit outpatient clinics to get two or more kinds of vaccines at the same time: pneumococcal vaccine, influenza vaccine, Td (diphtheria and tetanus) vaccine, HPV (human papilloma virus) vaccine, meningococcal vaccine, zoster vaccine, etc. This study is intended to evaluate the immunogenicity and safety (...) Posted: August 27, 2014 Last Verified: August 2014 Additional relevant MeSH terms: Layout table for MeSH terms Influenza, Human Pneumococcal Infections Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases Streptococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Vaccines Heptavalent Pneumococcal Conjugate Vaccine Immunologic Factors Physiological Effects of Drugs

2014 Clinical Trials

191. Manipulated Microenvironment in Human Papilloma Virus-Infected Epithelial Cells: Is the CD40-CD154 Pathway Beneficial for Host or Virus? Full Text available with Trip Pro

Manipulated Microenvironment in Human Papilloma Virus-Infected Epithelial Cells: Is the CD40-CD154 Pathway Beneficial for Host or Virus? In this issue, Tummers et al. (2014) demonstrate that high-risk human papilloma viruses (hrHPVs) attenuate the magnitude of responses to CD40 ligation and the epithelial cells' (ECs) capacity to attract leukocytes. These results suggest that hrHPVs can escape from host immune surveillance by modulating pro-inflammatory responses in infected ECs, resulting

2014 Journal of Investigative Dermatology

192. Effect of decision support on missed opportunities for human papillomavirus vaccination. Full Text available with Trip Pro

Effect of decision support on missed opportunities for human papillomavirus vaccination. Missed opportunities for human papilloma virus (HPV) vaccination are common, presenting a barrier to achieving widespread vaccine coverage and preventing infection.To compare the impact of clinician- versus family-focused decision support, none, or both on captured opportunities for HPV vaccination.Twelve-month cluster randomized controlled trial conducted in 2010-2011.Adolescent girls aged 11-17 years due (...) , or no intervention.Standardized proportions of captured opportunities (due vaccine received at clinician visit) were calculated among girls in each study arm. Analyses were conducted in 2013.Among 17,016 adolescent girls and their 32,472 visits (14,247 preventive, 18,225 acute), more HPV opportunities were captured at preventive than acute visits (36% vs 4%, p<0.001). At preventive visits, the clinician intervention increased captured opportunities by 9 percentage points for HPV-1 and 6 percentage points for HPV-3 (p≤0.01

2014 American journal of preventive medicine Controlled trial quality: uncertain

193. Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Full Text available with Trip Pro

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Human papilloma viruses can induce warts, condylomas, and other intraepithelial cervical lesions that can progress to cancer. Cervical cancer is a serious problem in developing countries because early detection is difficult, and thus proper early treatment is many times missing. In this phase III clinical trial, we evaluated the potential use of MVA E2 recombinant vaccinia virus to treat (...) intraepithelial lesions associated with papillomavirus infection. A total of 1176 female and 180 male patients with intraepithelial lesions were studied. They were injected with 10(7) MVA E2 virus particles directly into their uterus, urethra, vulva, or anus. Patients were monitored by colposcopy and cytology. Immune response was determined by measuring the antibody titer against MVA E2 virus and by analyzing the cytotoxic activity against cancer cells bearing papillomavirus DNA. Papillomavirus was determined

2014 Human gene therapy Controlled trial quality: uncertain

194. Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County

Bastani, University of California, Los Angeles: Human Papillomavirus Immunization Oncogenic viruses Cervical Cancer Health Disparities Additional relevant MeSH terms: Layout table for MeSH terms Virus Diseases Papilloma Papillomavirus Infections Neoplasms, Squamous Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms DNA Virus Infections Tumor Virus Infections Vaccines Immunologic Factors Physiological Effects of Drugs (...) completion rates (3 doses) at follow-up compared to the control group. Condition or disease Intervention/treatment Phase Human Papilloma Virus Infection Behavioral: Tailored education and referral Behavioral: Staff training and patient reminders Behavioral: Clinic-level reminder systems Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120000 participants Allocation: Randomized Intervention Model: Parallel Assignment

2014 Clinical Trials

195. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: Successful treatment with the quadrivalent human papillomatosis vaccine. (Abstract)

Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: Successful treatment with the quadrivalent human papillomatosis vaccine. Authors present a case report of a 2-year-old boy with recurrent laryngeal papillomatosis with oesophageal involvement due to human papilloma virus types 6 and 11, who needed surgical treatment every 4-6 weeks, altogether 11 times. After detailed immunological evaluation of basic immunological parameters, and in vitro detection of good (...) responses to routine childhood immunization, a therapeutic vaccination has been decided with a 4-valent HPV vaccine. Following the third vaccine dose both laryngeal and oesophageal lesions disappeared completely, and for 2 years follow-up no papillomas could be detected. Vaccination could be a promising method in the treatment of RRP in children. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

2014 International Journal of Pediatric Otorhinolaryngology

196. The vaccine study you’ll never see

a clear boundary, we’re going to build a wall and make Mercola pay for it. Now to the vaccine part: our “intervention.” Group A would follow the , which allegedly protects children from a long list of diseases (diphtheria, tetanus, pertussis, Hemophilus influenzae type B, pneumococcus, polio, rotavirus, hepatitis A, hepatitis B, measles, mumps, rubella, chickenpox, human papilloma virus, meningococcus, and influenza). We’ll see how true that really is. Group B would go to all the same doctor’s visits (...) ) why we haven’t done this study — and why we never will. Vaccines prevent disease — in your child, your child’s friends, and people who can’t be vaccinated. Vaccines save lives. No, we don’t have a double-blinded, randomized controlled trial comparing our vaccine schedule to placebo. But we do have some pretty convincing evidence. . Chad Hayes is a pediatrician who blogs at his self-titled site, . Image credit: Chad Hayes … … 7K Shares Tagged as: Subscribe to KevinMD and never miss a story! Get

2017 KevinMD blog

197. Both tumour cells and infiltrating T-cells in equine sarcoids express FOXP3 associated with an immune-supressed cytokine microenvironment Full Text available with Trip Pro

BPV induced fibro-papillomas of cattle (the natural host of BPV), in that they do not produce high amounts of virus particles, do not usually regress spontaneously and do not sero-convert to BPV; features which suggest that affected horses lack an effective anti-viral immune response to BPV. Equine sarcoids contain large numbers of CD4+ CD8+ dual positive T-cells which uniformly express FOXP3, the key transcription factor of regulatory T-cells, and FOXP3 is also expressed within the BPV infected (...) Both tumour cells and infiltrating T-cells in equine sarcoids express FOXP3 associated with an immune-supressed cytokine microenvironment Bovine papillomavirus (BPV) infections of equine species have a central role in the aetiology of equine sarcoids; a common benign skin tumour of horses, zebras and donkeys. Within the lesions, all of the early papillomavirus genes are expressed and promote the excessive replication of fibroblasts which characterise these tumours. Equine sarcoids differ from

2016 Veterinary Research

198. Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

the effects of other drugs in a site-specific, light-directed manner and is used to re-localise endocytosed molecules from endosomes to cytosol. This research study is evaluating the use of the PCI Technology in combination with adjuvant and vaccine antigens for safety and induction of immune responses. Condition or disease Intervention/treatment Phase Healthy Volunteer Drug: Fimaporfin (Photosensitizer) Biological: Hiltonol (Poly-ICLC) Biological: HPV E7 (Human Papilloma Virus E7) peptides Biological (...) , adjuvant and antigens Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application. Drug: Fimaporfin (Photosensitizer) Biological: Hiltonol (Poly-ICLC) Biological: HPV E7 (Human Papilloma Virus E7) peptides Biological: KLH (Keyhole Limpet Hemocyanin) Experimental: Assessments of time between ID dosing and light Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens

2016 Clinical Trials

199. Vaccinations for rheumatoid arthritis. Full Text available with Trip Pro

highlight the use of influenza, pneumococcal, and shingles vaccines in RA patients. Studies suggest influenza and pneumococcal vaccines are underutilized, but well tolerated in RA patients and generally immunogenic during DMARD use with the exception of rituximab. Though data for other nonlive vaccines are more limited, hepatitis B virus and human papilloma virus vaccines also appear well tolerated and immunogenic in this population. Live vaccines for shingles and yellow fever remain contraindicated (...) Vaccinations for rheumatoid arthritis. Rheumatoid arthritis (RA) patients experience increased infectious disease-related morbidity and mortality, and vaccinations represent an important element in their care. However, vaccine immunogenicity can be affected by disease-modifying antirheumatic drug (DMARD) therapy, such that vaccine choice and timing can be clinically challenging. We review the indications, safety, and immunogenicity of vaccines in the setting of RA.Recent recommendations

2016 Current Opinion in Rheumatology

200. Menveo - meningococcal group A, C, W-135 and Y conjugate vaccine

(MenactraTM, Sanofi Aventis; MenomuneTM, Aventis Pasteur); Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap: BoostrixTM [EU formulation in V59P11 and US formulation in V59P18]); and Human Papilloma Virus (HPV) vaccine (GardasilTM, Merck). Page 23/58 Scientific advice regarding the clinical development programme was sought on several occasions from the UK regulatory authority and the CHMP. The following essential issues were put forward in the initial scientific (...) data based on applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies). The applicant applied for the following indication: Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations. Information on Paediatric requirements

2010 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>